Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

520
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
520
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

367
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
367

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A pan-cancer functional atlas of ADH1A reveals its conserved role in the tumor microenvironment and immunity.

Translational cancer research·2026
Same author

Refined AI-ASPECTS with modified atlas and lesion-load thresholds: advancing acute ischemic stroke imaging and prognostic prediction.

BMC medicine·2026
Same author

Effectiveness of the dual teachers-three rings-four dimensions teaching model in cultivating nursing students' comprehensive competence: A quasi-experimental study.

Nurse education today·2026
Same author

Genomic Characterization and Molecular Detection of a Novel <i>Carlavirus</i> Infecting <i>Angelica dahurica</i>: <i>Angelica carlavirus Virus</i>.

Microorganisms·2026
Same author

Sepsis-3 improves risk stratification in Stevens-Johnson syndrome/toxic epidermal necrolysis with infection.

Journal of the American Academy of Dermatology·2026
Same author

A multi-omics map of diabetic nephropathy reveals c-Jun as a driver of tubular injury and metabolic stress.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Aug 22, 2025

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

8.8K

DEXMEDETOMIDINE PREVENTS PDIA3 DECREASE BY ACTIVATING α2-ADRENERGIC RECEPTOR TO ALLEVIATE INTESTINAL I/R IN MICE.

Yaqing Zhan1, Zhaorong Chen, Yuxin Qiu

  • 1Department of Anesthesiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Shock (Augusta, Ga.)
|November 14, 2022
PubMed
Summary

Dexmedetomidine (DEX) protects against intestinal ischemia-reperfusion (I/R) injury by maintaining protein disulfide isomerase A3 (PDIA3) levels via alpha2-adrenergic receptor (α2-AR) activation, reducing inflammation and apoptosis.

More Related Videos

Acquisition of Resting-State Functional Magnetic Resonance Imaging Data in the Rat
12:41

Acquisition of Resting-State Functional Magnetic Resonance Imaging Data in the Rat

Published on: August 28, 2021

4.4K
Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model
05:09

Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model

Published on: April 28, 2023

1.0K

Related Experiment Videos

Last Updated: Aug 22, 2025

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

8.8K
Acquisition of Resting-State Functional Magnetic Resonance Imaging Data in the Rat
12:41

Acquisition of Resting-State Functional Magnetic Resonance Imaging Data in the Rat

Published on: August 28, 2021

4.4K
Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model
05:09

Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model

Published on: April 28, 2023

1.0K

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Cell Biology

Background:

  • Dexmedetomidine (DEX) is known to mitigate intestinal ischemia-reperfusion (I/R) injury.
  • The precise mechanisms underlying DEX's protective effects, particularly its interaction with Protein disulfide isomerase A3 (PDIA3), require further investigation.
  • PDIA3 has emerged as a potential therapeutic target for intestinal I/R injury.

Purpose of the Study:

  • To determine if PDIA3 is involved in the protective effects of DEX against intestinal I/R injury.
  • To elucidate the underlying molecular mechanisms by which DEX confers intestinal protection.
  • To investigate the role of the alpha2-adrenergic receptor (α2-AR) in DEX-mediated intestinal protection.

Main Methods:

  • Utilized PDIA3 Flox/Flox and PDIA3 conditional knockout (cKO) mice to assess PDIA3's role in DEX's protective effects.
  • Induced intestinal I/R injury through superior mesenteric artery occlusion and reperfusion in mouse models.
  • Administered yohimbine, an α2-AR antagonist, to wild-type mice undergoing intestinal I/R to evaluate the involvement of α2-AR.

Main Results:

  • DEX administration significantly attenuated intestinal I/R-induced inflammation, endoplasmic reticulum (ER) stress-dependent apoptosis, and oxidative stress.
  • Deletion of PDIA3 in the intestinal epithelium (cKO) abrogated the protective effects of DEX.
  • Yohimbine treatment reversed DEX's protective effects and reduced PDIA3 expression, indicating α2-AR mediation.

Conclusions:

  • Dexmedetomidine (DEX) exerts protective effects against intestinal I/R injury by preventing the decrease of Protein disulfide isomerase A3 (PDIA3).
  • This protection is mediated through the activation of alpha2-adrenergic receptors (α2-AR).
  • DEX inhibits inflammation, ER stress-induced apoptosis, and oxidative stress in the context of intestinal I/R injury via PDIA3 and α2-AR pathways.